Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Vyome Holdings, Inc. (HIND) vs NeuroSense Therapeutics Ltd. (NRSN)

Vyome Holdings, Inc. and NeuroSense Therapeutics Ltd. are both Biotechnology companies. Vyome Holdings, Inc. and NeuroSense Therapeutics Ltd. are of similar size ($14.5M and $14.0M). NeuroSense Therapeutics Ltd. has negative trailing earnings, so its P/E is not meaningful; Vyome Holdings, Inc. trades at 0.0×. NeuroSense Therapeutics Ltd. has the higher net margin (0.00% vs −8,711.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 10 metrics below, NeuroSense Therapeutics Ltd. leads on 6 and Vyome Holdings, Inc. on 4.

Valuation

Metric HIND NRSN Biotechnology median
P/E 0.00 n/m 7.88
P/S 110.31 n/m 11.47
P/B 1.96 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 78.55 n/m 10.73
Earnings yield 74,921.03% (179.97%) (28.84%)
Free cash flow yield (38.96%) (339.53%) (23.03%)

Profitability

Metric HIND NRSN Biotechnology median
Gross margin 52.77% — 65.16%
Operating margin (9,184.82%) 0.00% 0.00%
Net margin (8,711.71%) 0.00% 0.00%
Free cash flow margin (4,298.00%) 0.00% 0.00%
Return on equity (172.10%) 0.00% (57.72%)
Return on assets (124.23%) 0.00% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric HIND NRSN Biotechnology median
Revenue growth (TTM) 103.81% — 5.64%
EPS growth (last fiscal year) 99.92% 20.45% —
Revenue growth, 5-year CAGR (50.98%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric HIND NRSN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.37 0.71 4.73
Net debt to EBITDA 0.48 0.01 0.96

Dividend

Metric HIND NRSN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric HIND NRSN Biotechnology median
Market cap 14.46m 14.04m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack